Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study and failed to disclose the declining relevance of viral-based editing. On January 9, 2025, Intellia announced a major reorganization, halting NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 03, 2025 | 4:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Potential legal and financial risks emerge from class action lawsuit and strategic research pivot, which could negatively impact investor confidence
The lawsuit and sudden research program cancellation suggest significant internal challenges, which could erode investor trust and potentially lead to further stock price pressure
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100